The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index; none of the 41 sources its claims cite is checked for support yet.
Virus-Dependent Phosphorylation of the IRF-3 Transcription Factor Regulates Nuclear Translocation, Transactivation Potential, and Proteasome-Mediated Degradation
Open accessAbstract
The interferon regulatory factors (IRF) consist of a growing family of related transcription proteins first identified as regulators of the alpha beta interferon (IFN-alpha/beta) gene promoters, as well as the interferon-stimulated response element (ISRE) of some IFN-stimulated genes. IRF-3 was originally identified as a member of the IRF family based on homology with other IRF family members and on binding to the ISRE of the ISG15 promoter. IRF-3 is expressed constitutively in a variety of tissues, and the relative levels of IRF-3 mRNA do not change in virus-infected or IFN-treated cells. In the present study, we demonstrate that following Sendai virus infection, IRF-3 is posttranslationally modified by protein phosphorylation at multiple serine and threonine residues, which are located in the carboxy terminus of IRF-3. A combination of IRF-3 deletion and point mutations localized the inducible phosphorylation sites to the region -ISNSHPLSLTSDQ- between amino acids 395 and 407; point mutation of residues Ser-396 and Ser-398 eliminated virus-induced phosphorylation of IRF-3 protein, although residues Ser-402, Thr-404, and Ser-405 were also targets. Phosphorylation results in the cytoplasm-to-nucleus translocation of IRF-3, DNA binding, and increased transcriptional activation. Substitution of the Ser-Thr sites with the phosphomimetic Asp generated a constitutively active form of IRF-3 that functioned as a very strong activator of promoters containing PRDI-PRDIII or ISRE regulatory elements. Phosphorylation also appears to represent a signal for virus-mediated degradation, since the virus-induced turnover of IRF-3 was prevented by mutation of the IRF-3 Ser-Thr cluster or by proteasome inhibitors. Interestingly, virus infection resulted in the association of IRF-3 with the CREB binding protein (CBP) coactivator, as detected by coimmunoprecipitation with anti-CBP antibody, an interaction mediated by the C-terminal domains of both proteins. Mutation of residues Ser-396 and Ser-398 in IRF-3 abrogated its binding to CBP. These results are discussed in terms of a model in which virus-inducible, C-terminal phosphorylation of IRF-3 alters protein conformation to permit nuclear translocation, association with transcriptional partners, and primary activation of IFN- and IFN-responsive genes.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
In Sendai virus-infected cells, IRF-3 is phosphorylated at C-terminal Ser/Thr residues, which drives nuclear translocation, DNA binding/transactivation, CBP association, and subsequent proteasome-mediated degradation. Phosphomimetic IRF-3(5D) acts as a constitutive strong activator of IFN-β and ISG-15 promoters.
Key findings
- Virus-induced phosphorylation mapped to the C-terminal region -ISNSHPLSLTSDQ- between amino acids 395 and 407; Ser-396 and Ser-398 were critical, since IRF-3(2A) and IRF-3(5A) eliminated virus-induced phosphorylation, while IRF-3(3A) was weakly phosphorylated, implicating Ser-402, Thr-404, and Ser-405 as secondary sites.
- Phosphorylation was required for cytoplasm-to-nucleus translocation: Sendai virus induced nuclear translocation in 90 to 95% of cells within 8 h, GFP–IRF-3(5A) completely abrogated this, and GFP–IRF-3(5D) localized partly to the nucleus in uninfected cells and intensely to the nucleus after infection.
- IRF-3(5D) alone stimulated the IFN-β promoter by 90-fold and the ISG-15 promoter by 50-fold; with RelA(p65), IRF-3(5D) produced an 80-fold stimulation of IFN-β, while IRF-3(407) stimulated IFN-β about 6-fold and ISG-15 12-fold.
- Phosphorylation signaled proteasome-mediated degradation and CBP binding: calpain inhibitor I or MG132 blocked virus-induced IRF-3 degradation, IRF-3(5A) was resistant, and IRF-3 coimmunoprecipitated with CBP only from virus-infected cells, requiring Ser-396/Ser-398 and the C-terminal CBP-3 domain.
Methods
- Transient transfections were performed in human embryonic kidney 293 cells, murine NIH 3T3 cells, and COS-7 cells, plus a stable rtTA-IRF-3 293 line; cells were infected with Sendai virus at 80 hemagglutinating units/ml, and IRF-3 deletion and point mutants were generated by PCR mutagenesis.
- Analyses included Western blotting for IRF-3 mobility and degradation, phosphatase treatment with PPA or CIP, CAT reporter assays for IFN-β (SVoβ CAT) and ISG-15 promoters normalized to β-galactosidase, EMSA with PRDIII or ISRE probes, GFP–IRF-3 fluorescence microscopy, and coimmunoprecipitation with anti-CBP or anti-myc antibodies.
Limitations
- The paper states that the nature of the subnuclear changes in IRF-3(NES) localization is not explained, it is unclear whether the upper virus-induced protein-DNA complex contains other proteins such as VIC or DRAF or whether the lower complex is an IRF-3 breakdown product, the functional consequences of IRF-3 interaction with CBP/p300 remain to be elucidated, and the nuclear localization sequence is unidentified.
- Evident from the text: many experiments rely on transfected or overexpressed IRF-3 in immortalized cell lines, with endogenous IRF-3 turnover sometimes more pronounced than that of transfected protein; no in vivo animal model is presented, and some supporting observations are cited as unpublished data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 41 cited sources checked · 0 supported · 0 flagged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Substitution of the Ser-Thr sites with the phosphomimetic Asp generated a constitutively active form of IRF-3 that functioned as a very strong activator of promoters containing PRDI-PRDIII or ISRE regulatory elements.”
- Also stated in: § RESULTS · boosted
“Strikingly, the substitution of the Ser-Thr cluster at aa 396 to 405 in IRF-3 with the phosphomimetic Asp generated a very strong, constitutive transactivator protein that alone stimulated the IFN-β promoter by 90-fold.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § RESULTS · boosted
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“point mutation of residues Ser-396 and Ser-398 eliminated virus-induced phosphorylation of IRF-3 protein”
- Also stated in: § RESULTS · hedged
“These experiments thus implicate Ser-396 and Ser-398 as critical sites of virus-induced phosphorylation of IRF-3”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § RESULTS · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A combination of IRF-3 deletion and point mutations localized the inducible phosphorylation sites to the region -ISNSHPLSLTSDQ- between amino acids 395 and 407”
- Also stated in: § RESULTS · plain
“Thus, by deletion analysis, a phosphorylation domain of IRF-3 protein was localized to the region -ISNSHPLSLTSDQ- between aa 395 and 407.”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in studies with the S385A and S386A mutation, we found no evidence for inducible phosphorylation at these sites”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“although residues Ser-402, Thr-404, and Ser-405 were also targets.”
- Also stated in: § RESULTS · plain
“residues Ser-402, Thr-404, and Ser-405 also contribute to the observed phosphorylation”
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the present study, we demonstrate that following Sendai virus infection, IRF-3 is posttranslationally modified by protein phosphorylation at multiple serine and threonine residues, which are located in the carboxy terminus of IRF-3.”
- Also stated in: § RESULTS · hedged
“The results indicated that virus-induced phosphorylation of IRF-3 occurs at the C-terminal end of IRF-3”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § RESULTS · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Sendai virus infection resulted in two alterations in the expression of IRF-3: an overall decrease in the amount of IRF-3 in transfected and control cells”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, in uninfected cells, IRF-3(5D) localized in part to the nucleus (Fig. 5)”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Rests on an assumption: Phosphomimetic Asp at the sites of C-terminal phosphorylation functionally mimics phosphorylation.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the IRF-3-ΔN5A protein was resistant to virus-induced degradation”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Interestingly, virus infection resulted in the association of IRF-3 with the CREB binding protein (CBP) coactivator, as detected by coimmunoprecipitation with anti-CBP antibody”
- Also stated in: § RESULTS · plain
“an immunoblot for IRF-3 revealed that IRF-3 was coprecipitated from virus-infected cells but not from uninfected cells”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § RESULTS · plain
- It may state two separate claims as one. 23
- Probably not a substantial claim. 21
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The residues implicated in this regulatory phosphorylation event are Ser-396, Ser-398, Ser-402, Thr-404, and Ser-405, particularly the Ser-396 and Ser-398 residues.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“IRF-3(357) did not stimulate gene expression but rather slightly repressed ISG-15”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“IRF-3 alone weakly activated the ISG-15 promoter; in the context of this regulatory element, IRF-3 was weaker than IRF-1, which produced a 9-fold stimulation”
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This interaction was observed clearly in cells cotransfected with the IRF-3 expression plasmid (Fig. 8B, lane 3) but was not seen when the immunoprecipitation was performed with preimmune serum”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Immunoblot analysis of the whole-cell extracts revealed that phosphorylated IRF-3, as well as forms I and II, was present in virus-infected cells (Fig. 8B, lane 10), and in cells transfected with 2A, 3A, and 5A the forms I and II but not the phosphorylated form of IRF-3 were observed”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In uninfected cells, GFP–IRF-3 localized exclusively to the cytoplasm; Sendai virus infection resulted in translocation of IRF-3 to the nucleus within 8 h in 90 to 95% of the cells”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“virus-induced degradation of full-length (endogenous) forms of IRF-3 (Fig. 7A, lanes 1 and 4) and the truncated ΔN (Fig. 7B, lanes 1 and 4) was detected”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“IRF-3(2A) and IRF-3(5A) were detected in whole-cell extract immunoblot but not in the CBP immunoprecipitate”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“no further stabilization of IRF-3-ΔN5A occurred with calpain inhibitor I or MG132 addition, and no phosphorylated IRF-3 was detected”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“IRF-3(5D) localized both to the nucleus and to the cytoplasm in uninfected cells (Fig. 5E), while virus infection resulted in an intense nuclear pattern of IRF-3(5D) fluorescence”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“In the case of IRF-3, phosphorylation is not detected until 6 to 8 h after infection and continues in a heterogeneous manner over the following 10 to 12 h.”
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“whereas IRF-3 phosphorylation appears to be induced only by virus infection and dsRNA addition; other inducers have not resulted in IRF-3 turnover (40a).”
What the sources say
- Not checked yetcites 40a
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Furthermore, the protease inhibitor calpain inhibitor I and the more specific proteasome inhibitor MG132 block IRF-3 turnover.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“since mutation of Ser-396 and Ser-398 or the use of proteasome inhibitors prevented postinfection degradation of IRF-3.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“IRF-3 is expressed constitutively in a variety of tissues, and the relative levels of IRF-3 mRNA do not change in virus-infected or IFN-treated cells.”
- Also stated in: § Abstract · plain
“The IRF-3 gene encodes a 55-kDa protein which is expressed constitutively in all tissues.”
What the sources say
- Not checked yetcites [2] Au W-C, Moore P A, Lowther W, Juang Y-T, Pitha P M. Identification of a member of the interferon regulatory factor family that binds to the interferon-stimulated response element and activates expression of interferon-induced genes. Proc Natl Acad Sci USA. 1995;92:11657–11661. doi: 10.1073/pnas.92.25.11657. [DOI] [PMC free article] [PubMed] [Google Scholar]
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Abstract · plain
None of the sources cited for this claim have been checked yet.
In the paper
“As a critical determinant of its global transcriptional coactivator activity, CBP/p300 possesses histone acetyltransferase activity (5, 50).”
What the sources say
- Not checked yetcites [5] Bannister A J, Kouzarides T. The CBP coactivator is a histone acetyltransferase. Nature. 1996;384:641–643. doi: 10.1038/384641a0. [DOI] [PubMed] [Google Scholar]
- Not checked yetcites [50] Ogryzko V V, Schiltz R L, Russanova V, Howard B H, Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell. 1996;87:953–959. doi: 10.1016/s0092-8674(00)82001-2. [DOI] [PubMed] [Google Scholar]
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These results are discussed in terms of a model in which virus-inducible, C-terminal phosphorylation of IRF-3 alters protein conformation to permit nuclear translocation, association with transcriptional partners, and primary activation of IFN- and IFN-responsive genes.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“The recent crystal structure of the related IRF-1 protein bound to PRDI provides evidence for a novel helix-turn-helix motif that latches onto a GAAA core sequence via three of the five conserved tryptophan amino acids of the DNA binding domain (20).”
What the sources say
- Not checked yetcites [20] Escalante C R, Yie J, Thanos D, Aggarwal A K. Structure of IRF-1 with bound DNA reveals determinants of interferon regulation. Nature. 1998;391:103–106. doi: 10.1038/34224. [DOI] [PubMed] [Google Scholar]
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“In previous experiments, we demonstrated that IRF-3 was able to bind the ISRE element of ISG-15, as well as the PRDIII-PRDI and IE regions of the IFN-β and IFN-α promoters, respectively (2, 56).”
What the sources say
- Not checked yetcites [2] Au W-C, Moore P A, Lowther W, Juang Y-T, Pitha P M. Identification of a member of the interferon regulatory factor family that binds to the interferon-stimulated response element and activates expression of interferon-induced genes. Proc Natl Acad Sci USA. 1995;92:11657–11661. doi: 10.1073/pnas.92.25.11657. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Not checked yetcites [56] Schafer S, Lin R, Moore P, Hiscott J, Pitha P M. Regulation of type 1 interferon gene expression by interferon regulatory factor 3. J Biol Chem. 1998;273:2714–2720. doi: 10.1074/jbc.273.5.2714. [DOI] [PubMed] [Google Scholar]
Strength:boosted· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Elegant studies published during review of the manuscript demonstrated that synergistic activation of the IFN-β promoter requires recruitment of CBP/p300 to the enhanceosome, via a new activating surface assembled from the activation domains of all of the transcription factors in the enhanceosome (37, 45).”
What the sources say
- Not checked yetcites [37] Kim T K, Maniatis T. The mechanism of transcriptional synergy of an in vitro assembled interferon β enhanceosome. Mol Cell. 1998;1:119–129. doi: 10.1016/s1097-2765(00)80013-1. [DOI] [PubMed] [Google Scholar]
- Not checked yetcites [45] Merika M, Williams A, Chen G, Collins T, Thanos D. Recruitment of CBP/p300 by the IFNβ enhanceosome is required for synergistic activation of transcription. Mol Cell. 1998;1:277–287. doi: 10.1016/s1097-2765(00)80028-3. [DOI] [PubMed] [Google Scholar]
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“although Ser-402, Ser-404, and Ser-405 may represent secondary phosphorylation sites.”
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Upon stimulation by many activating agents, including cytokines, viruses, and dsRNA, IκBα is rapidly phosphorylated and degraded, resulting in the release and nuclear translocation of NF-κB.”
What the sources say
- Not checked yetcites [4] Baldwin A S., Jr The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol. 1996;14:649–681. doi: 10.1146/annurev.immunol.14.1.649. [DOI] [PubMed] [Google Scholar]
- Not checked yetcites [6] Beauparlant P, Hiscott J. Biological and biochemical inhibitors of the NF-κB/Rel proteins and cytokine synthesis. Cytokine Growth Factor Rev. 1996;7:175–190. doi: 10.1016/1359-6101(96)00020-2. [DOI] [PubMed] [Google Scholar]
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Although TH3 has been shown to bind DNA and to repress transcription more efficiently than the full-length IRF-2 protein (42)”
What the sources say
- Not checked yetcites [42] Lin R, Mustafa A, Nguyen H, Hiscott J. Mutational analysis of interferon (IFN) regulatory factors 1 and 2: effects on the induction of IFN-β gene expression. J Biol Chem. 1994;269:17542–17549. [PubMed] [Google Scholar]
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Previous experiments, however, have demonstrated that Sendai virus-induced turnover of IκBα also occurs slowly over several hours (24).”
What the sources say
- Not checked yetcites [24] Garoufalis E, Kwan I, Lin R, Mustafa A, Pepin N, Roulston A, Lacoste J, Hiscott J. Viral induction of the human interferon beta promoter: modulation of transcription by NF-κB/rel proteins and interferon regulatory factors. J Virol. 1994;68:4707–4715. doi: 10.1128/jvi.68.8.4707-4715.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“interestingly, CBP/p300 was shown recently to acetylate p53 and to stimulate its transactivation potential (28).”
What the sources say
- Not checked yetcites [28] Gu W, Roeder R G. Activation of p53 sequence-specific DNA binding by acetylation of p53 C-terminal domain. Cell. 1997;90:595–606. doi: 10.1016/s0092-8674(00)80521-8. [DOI] [PubMed] [Google Scholar]
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In response to double-stranded RNA (dsRNA) or viral induction, the 50-kDa IRF-2 protein is proteolytically processed into a smaller, 24- to 27-kDa protein (51) comprising the 160-aa DNA-binding domain (DBD) of IRF-2, which was termed TH3 (14) or In4 (65).”
What the sources say
- Not checked yetcites [51] Palombella V J, Maniatis T. Inducible processing of interferon regulatory factor-2. Mol Cell Biol. 1992;12:3325–3336. doi: 10.1128/mcb.12.8.3325-3336.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Not checked yetcites [14] Cohen L, Hiscott J. Characterization of TH3, an induction specific protein interacting with the interferon-β promoter. Virology. 1992;191:589–599. doi: 10.1016/0042-6822(92)90234-g. [DOI] [PubMed] [Google Scholar]
- Not checked yetcites [65] Whiteside S T, King P, Goodbourn S. A truncated form of the IRF-2 transcription factor has the properties of a postinduction repressor of interferon-β gene expression. J Biol Chem. 1994;269:27059–27065. [PubMed] [Google Scholar]
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“The amino terminus of IκBα is necessary for signal-induced phosphorylation and ubiquitination, but for degradation to occur, there is an absolute requirement for the C-terminal PEST domain (reviewed in references 4 and 6).”
What the sources say
- Not checked yetcites [4] Baldwin A S., Jr The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol. 1996;14:649–681. doi: 10.1146/annurev.immunol.14.1.649. [DOI] [PubMed] [Google Scholar]
- Not checked yetcites [6] Beauparlant P, Hiscott J. Biological and biochemical inhibitors of the NF-κB/Rel proteins and cytokine synthesis. Cytokine Growth Factor Rev. 1996;7:175–190. doi: 10.1016/1359-6101(96)00020-2. [DOI] [PubMed] [Google Scholar]
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“substitution of alanine for either Ser-32 or Ser-36 completely abolished the signal-induced phosphorylation and degradation of IκBα and blocked activation of NF-κB.”
What the sources say
- Not checked yetcites [4] Baldwin A S., Jr The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol. 1996;14:649–681. doi: 10.1146/annurev.immunol.14.1.649. [DOI] [PubMed] [Google Scholar]
- Not checked yetcites [6] Beauparlant P, Hiscott J. Biological and biochemical inhibitors of the NF-κB/Rel proteins and cytokine synthesis. Cytokine Growth Factor Rev. 1996;7:175–190. doi: 10.1016/1359-6101(96)00020-2. [DOI] [PubMed] [Google Scholar]
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In unstimulated cells, NF-κB heterodimers are retained in the cytoplasm by inhibitory IκB proteins.”
What the sources say
- Not checked yetcites [4] Baldwin A S., Jr The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol. 1996;14:649–681. doi: 10.1146/annurev.immunol.14.1.649. [DOI] [PubMed] [Google Scholar]
- Not checked yetcites [6] Beauparlant P, Hiscott J. Biological and biochemical inhibitors of the NF-κB/Rel proteins and cytokine synthesis. Cytokine Growth Factor Rev. 1996;7:175–190. doi: 10.1016/1359-6101(96)00020-2. [DOI] [PubMed] [Google Scholar]
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“A growing body of biochemical and genetic evidence also implicates CBP/p300 as a negative regulator of cell growth, based on its interactions with adenovirus E1a, simian virus 40 large T antigen, and the tumor suppressor p53 among others.”
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Likewise, in the case of IκBα, phosphorylation of Ser-32 and Ser-36 are required for inducer-mediated degradation.”
What the sources say
- Not checked yetcites [4] Baldwin A S., Jr The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol. 1996;14:649–681. doi: 10.1146/annurev.immunol.14.1.649. [DOI] [PubMed] [Google Scholar]
- Not checked yetcites [6] Beauparlant P, Hiscott J. Biological and biochemical inhibitors of the NF-κB/Rel proteins and cytokine synthesis. Cytokine Growth Factor Rev. 1996;7:175–190. doi: 10.1016/1359-6101(96)00020-2. [DOI] [PubMed] [Google Scholar]
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Alterations in any of the activation domains decreased both CBP recruitment and transcriptional synergy.”
What the sources say
- Not checked yetcites [37] Kim T K, Maniatis T. The mechanism of transcriptional synergy of an in vitro assembled interferon β enhanceosome. Mol Cell. 1998;1:119–129. doi: 10.1016/s1097-2765(00)80013-1. [DOI] [PubMed] [Google Scholar]
- Not checked yetcites [45] Merika M, Williams A, Chen G, Collins T, Thanos D. Recruitment of CBP/p300 by the IFNβ enhanceosome is required for synergistic activation of transcription. Mol Cell. 1998;1:277–287. doi: 10.1016/s1097-2765(00)80028-3. [DOI] [PubMed] [Google Scholar]
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“functional interaction between these two important growth regulatory proteins accounts for several of the known activities of p53 (3, 29, 40)”
What the sources say
- Not checked yetcites [3] Avantaggiati M L, Ogryzko V, Gardner K, Giordano A, Levine A S, Kelly K. Recruitment of p300/CBP in p53-dependent signal pathways. Cell. 1997;89:1175–1184. doi: 10.1016/s0092-8674(00)80304-9. [DOI] [PubMed] [Google Scholar]
- Not checked yetcites [29] Gu W, Shi X L, Roeder R G. Synergistic activation of transcription by CBP and p53. Nature. 1997;387:819–823. doi: 10.1038/42972. [DOI] [PubMed] [Google Scholar]
- Not checked yetcites [40] Lill N L, Grossman S R, Ginsberg D, DeCaprio J, Livingston D M. Binding and modulation of p53 by p300/CBP coactivators. Nature. 1997;387:823–827. doi: 10.1038/42981. [DOI] [PubMed] [Google Scholar]
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“By analogy, recruitment of CBP/p300 to DNA-bound IRF-3 is likely required for maximal transcriptional activation.”
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Several studies have now demonstrated that CBP/p300 participates in the transcriptional process by providing a scaffold for different classes of transcriptional regulators on specific chromatin domains (12, 50).”
What the sources say
- Not checked yetcites [12] Chen H, Lin R J, Schiltz R L, Chakravarti D, Nash A, Nagy L, Privalsky M L, Nakatani Y, Evans R M. Nuclear receptor coactivator ACTR is a novel histone acetyltransferases and forms a multimeric activation complex with P/CAF and CBP/p300. Cell. 1997;90:569–580. doi: 10.1016/s0092-8674(00)80516-4. [DOI] [PubMed] [Google Scholar]
- Not checked yetcites [50] Ogryzko V V, Schiltz R L, Russanova V, Howard B H, Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell. 1996;87:953–959. doi: 10.1016/s0092-8674(00)82001-2. [DOI] [PubMed] [Google Scholar]
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“These mutations also blocked in vitro ubiquitination of the IκBα protein.”
What the sources say
- Not checked yetcites [4] Baldwin A S., Jr The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol. 1996;14:649–681. doi: 10.1146/annurev.immunol.14.1.649. [DOI] [PubMed] [Google Scholar]
- Not checked yetcites [6] Beauparlant P, Hiscott J. Biological and biochemical inhibitors of the NF-κB/Rel proteins and cytokine synthesis. Cytokine Growth Factor Rev. 1996;7:175–190. doi: 10.1016/1359-6101(96)00020-2. [DOI] [PubMed] [Google Scholar]
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“although recent studies demonstrated that CBP/p300 also functionally interacts with STAT1 (68) and STAT2 (7) and may contribute to IFN-α and IFN-γ nuclear signalling.”
What the sources say
- Not checked yetcites [68] Zhang J J, Vinkemeier U, Gu W, Chakravarti D, Horvath C M, Darnell J E. Two contact regions between STAT1 and CBP/p300 in interferon gamma signalling. Proc Natl Acad Sci USA. 1996;93:15092–15096. doi: 10.1073/pnas.93.26.15092. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Not checked yetcites [7] Bhattacharya S, Eckner R, Grossman S, Oldread E, Arany Z, D’Andrea A, Livingston D M. Cooperation of Stat2 and p300/CBP by interferon-α. Nature. 1996;383:344–347. doi: 10.1038/383344a0. [DOI] [PubMed] [Google Scholar]
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“a region previously shown to associate with the p53 tumor suppressor, whereas STAT1 and STAT2 associate with different regions of CBP (7, 68).”
What the sources say
- Not checked yetcites [7] Bhattacharya S, Eckner R, Grossman S, Oldread E, Arany Z, D’Andrea A, Livingston D M. Cooperation of Stat2 and p300/CBP by interferon-α. Nature. 1996;383:344–347. doi: 10.1038/383344a0. [DOI] [PubMed] [Google Scholar]
- Not checked yetcites [68] Zhang J J, Vinkemeier U, Gu W, Chakravarti D, Horvath C M, Darnell J E. Two contact regions between STAT1 and CBP/p300 in interferon gamma signalling. Proc Natl Acad Sci USA. 1996;93:15092–15096. doi: 10.1073/pnas.93.26.15092. [DOI] [PMC free article] [PubMed] [Google Scholar]
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper relies on this without support.
Phosphomimetic Asp at the sites of C-terminal phosphorylation functionally mimics phosphorylation.
“IRF-3 containing the phosphomimetic Asp at the sites of C-terminal phosphorylation”
The authors state this as an assumption.
IRF-3 exists in a latent state in the cytoplasm of uninfected cells.
“IRF-3 exists in a latent state in the cytoplasm of uninfected cells”
The authors state this as an assumption.
The C terminus of IRF-3 may physically interact with the DNA binding domain to obscure both the DBD and IAD regions.
“the C terminus may physically interact with the DNA binding domain in such a way as to obscure both the DBD and the IAD regions of the protein”
The authors state this as an assumption.
The C-terminal 20 aa (407 to 427) contains an autoinhibitory domain.
“the presence of an autoinhibitory domain within the C-terminal 20 aa (407 to 427)”
The authors state this as an assumption.
Translocation of IRF-3 to the nucleus occurs via an unidentified nuclear localization sequence or in conjunction with a transcriptional partner associating through the IAD region.
“Translocation to the nucleus, occurring via an unidentified nuclear localization sequence or in conjunction with a transcriptional partner associating through the IAD region”
The authors state this as an assumption.
The presence of a NES element ultimately shuttles IRF-3 from the nucleus and terminates the initial activation of IFN-responsive promoters.
“The presence of a NES element ultimately shuttles IRF-3 from the nucleus and terminates the initial activation of IFN-responsive promoters.”
The authors state this as an assumption.
The phosphorylated form of IRF-3 exported from the nucleus may then be susceptible to proteasome-mediated degradation.
“The phosphorylated form of IRF-3 exported from the nucleus may then be susceptible to proteasome-mediated degradation.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“IRF-3 possesses a C-terminal autoinhibitory region.Regulated phosphorylation of this region upon viral infection stimulates DNA binding”
From Assembly requirements of PU.1–Pip (IRF‐4) activator complexes: inhibiting function in vivo using fused dimers (1999) · cites this paper as Lin et al., 1998
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Figure 2B lane 6 cited for both presence and disappearance of phosphorylated IRF-3
MinorLane 6 is cited as showing the additional IRF-3 form in infected cells and also as showing its complete disappearance after phosphatase treatment.
“an additional slowly migrating, presumably phosphorylated form of IRF-3 was also detected (Fig. 2B, lane 6)”
“this form of IRF-3 completely disappeared following CIP or PPA treatment (Fig. 2B, lanes 6 and 7)”
Residue 404 identified as both threonine and serine
MinorThe mapped phosphorylation cluster identifies residue 404 as threonine, whereas the discussion calls it serine.
“Ser-402, Thr-404, and Ser-405”
“Ser-402, Ser-404, and Ser-405 may represent secondary phosphorylation sites.”
Different residues identified for the NES mutation
MinorThe results identify the nuclear export signal mutation as L145A-L146A, but the discussion identifies it as L144A and L145A.
“the L145A-L146A modification—termed IRF–3(nuclear export signal [NES])”
“Mutation of L144A and L145A in the NES element produced the most impressive alterations in subcellular localization.”
Citations
Cites
Darnell, J. E., Kerr, L. M., & Stark, G. R. (1994) · Science · doi:10.1126/science.8197455 · Cited by 6,080
THE NF-κB AND IκB PROTEINS: New Discoveries and Insights
Baldwin, A. S. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.649 · Cited by 5,882
Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.
Gossen, M., & Bujard, H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5547 · Cited by 4,943 · cited 1×
“The kinetics of virus-induced modification of IRF-3 in a 293 cell line that expressed IRF-3 inducibly under the control of the tetracycline-responsive promoter CMVt were characterized (26, 27).”
MethodThe Transcriptional Coactivators p300 and CBP Are Histone Acetyltransferases
Ogryzko, V. V., Schiltz, R. L., Russanova, V., Howard, B. H., & Nakatani, Y. (1996) · Cell · doi:10.1016/s0092-8674(00)82001-2 · Cited by 2,952
Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559
Transcriptional Activation by Tetracyclines in Mammalian Cells
Gossen, M., Freundlieb, S., Bender, G., Müller, G., Hillen, W., & Bujard, H. (1995) · Science · doi:10.1126/science.7792603 · Cited by 2,488 · cited 1×
“The kinetics of virus-induced modification of IRF-3 in a 293 cell line that expressed IRF-3 inducibly under the control of the tetracycline-responsive promoter CMVt were characterized (26, 27).”
MethodPhosphorylated CREB binds specifically to the nuclear protein CBP
Chrivia, J. C., Kwok, R. P. S., Lamb, N., Hagiwara, M., Montminy, M. R., & Goodman, R. H. (1993) · Nature · doi:10.1038/365855a0 · Cited by 2,052
The CBP co-activator is a histone acetyltransferase
Bannister, A. J., & Kouzarides, T. (1996) · Nature · doi:10.1038/384641a0 · Cited by 1,828
TRANSCRIPTIONAL RESPONSES TO POLYPEPTIDE LIGANDS: The JAK-STAT Pathway
Schindler, C., & Darnell, J. E. (1995) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.64.070195.003201 · Cited by 1,808
Chen, H., Lin, R. J., Schiltz, R. L., Chakravarti, D., Nash, A., Nagy, L., Privalsky, M. L., Nakatani, Y., & Evans, R. M. (1997) · Cell · doi:10.1016/s0092-8674(00)80516-4 · Cited by 1,480
Self-citation
Flagged first, then by citations
Research works printed but not linked: 3
- Crepieux P., 1994, Crit. Rev. Oncog., 5, 615
- Evan G. I., 1984, Mol. Cell. Biol., 4, 2843
- Nguyen, H., J. Hiscott, and P. M. Pitha. The growing family of IRF transcription factors. Cytokine Growth Factor Rev., in press.
Cited by
Sorted by citations
Items 501–600 of 923
Park, H., Kim, S.-J., Park, S., et al. (2013) · Life Sciences · doi:10.1016/j.lfs.2013.02.012 · Cited by 38
Persistent Cytomegalovirus Infection in Amniotic Membranes of the Human Placenta
Tabata, T., Petitt, M., Fang-Hoover, J., et al. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.07.016 · Cited by 38
The Adenovirus E1A C Terminus Suppresses a Delayed Antiviral Response and Modulates RAS Signaling
Zemke, N. R., & Berk, A. J. (2017) · Cell Host & Microbe · doi:10.1016/j.chom.2017.11.008 · Cited by 33
Majumdar, T., Sharma, S., Kumar, M., Hussain, M. A., Chauhan, N., Kalia, I., Sahu, A. K., Rana, V. S., Bharti, R., Haldar, A. K., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1420-9 · Cited by 39
Kienes, I., Bauer, S., Gottschild, C., Mirza, N., Pfannstiel, J., Schröder, M., & Kufer, T. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.653883 · Cited by 39
Grandvaux, N., Gaboriau, F., Harris, J., tenOever, B. R., Lin, R., & Hiscott, J. B. (2005) · FEBS Journal · doi:10.1111/j.1742-4658.2005.04726.x · Cited by 37
Self-citationJohnsen, I. B., Nguyen, T. T., Bergstrøm, B., Fitzgerald, K. A., & Anthonsen, M. W. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808233200 · Cited by 36
Goubau, D., van der Veen, A. G., Chakravarty, P., Lin, R., Rogers, N. C., Rehwinkel, J., Deddouche, S., Rosewell, I. R., Hiscott, J. B., & Sousa, C. R. E. (2015) · European Journal of Immunology · doi:10.1002/eji.201545794 · Cited by 34
Self-citationChen, Y., Yue, S., Yu, L., Cao, J., Liu, Y., Deng, A., Lu, Y., Yang, J., Li, Y., Du, J., et al. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s501773 · Cited by 44
Ourthiague, D., Birnbaum, H. A., Ortenlöf, N., Vargas, J. D., Wollman, R., & Hoffmann, A. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.4a1014-483rr · Cited by 31
IRF3-binding lncRNA-ISIR strengthens interferon production in viral infection and autoinflammation
Xu, J., Wang, P., Li, Z., Li, Z., Han, D., Wen, M., Zhao, Q., Zhang, L., Ma, Y., Liu, W., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109926 · Cited by 38
Tasaka‐Fujita, M., Sakamoto, N., Itakura, Y., Nakagawa, M., Itsui, Y., Sekine‐Osajima, Y., Nishimura‐Sakurai, Y., Chen, C., Yoneyama, M., Fujita, T., et al. (2007) · Journal of General Virology · doi:10.1099/vir.0.83056-0 · Cited by 36
Goffic, R. L., Mouchel, T., Aubry, F., et al. (2002) · Endocrinology · doi:10.1210/endo.143.4.8735 · Cited by 37
Park, S., Song, H., & Youn, H. (2009) · Molecules and Cells · doi:10.1007/s10059-009-0130-z · Cited by 37
Xie, R., van Wijnen, A. J., van der Meijden, C. M. J., Luong, M. X., Stein, J. L., & Stein, G. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010391200 · Cited by 37
Toscana virus induces interferon although its NSs protein reveals antagonistic activity
Savellini, G. G., Weber, F., Terrosi, C., Habjan, M., Martorelli, B., & Cusi, M. G. (2010) · Journal of General Virology · doi:10.1099/vir.0.025999-0 · Cited by 35
Zaritsky, L. A., Gama, L., & Clements, J. E. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003757 · Cited by 34
IRAK‐4 kinase activity‐dependent and ‐independent regulation of lipopolysaccharide‐inducible genes
Koziczak‐Holbro, M., Glück, A., Tschopp, C., Mathison, J. C., & Gram, H. (2008) · European Journal of Immunology · doi:10.1002/eji.200737886 · Cited by 36
Peng, T., Kotla, S., Bumgarner, R. E., & Gustin, K. E. (2006) · Journal of Virology · doi:10.1128/jvi.80.10.5021-5031.2006 · Cited by 36
RetractedCheung, P. H., Lee, T.-W. T., Kew, C., Chen, H., Yuen, K., Chan, C., & Jin, D. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008611 · Cited by 33
IRF5 Acts as a Potential Therapeutic Marker in Inflammatory Bowel Diseases
Yang, Y., Zhang, C., Jing, D., He, H., Li, X., Wang, Y., Qin, Y., Xiao, X., Xiong, H., & Zhou, G. (2020) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izaa200 · Cited by 32
Srinivasan, K., Pandey, A. K., Livingston, A., & Venkatesh, S. (2021) · Molecular Biomedicine · doi:10.1186/s43556-021-00060-1 · Cited by 36
Jordanovski, D., Herwartz, C., Pawlowski, A. E., Taute, S., Frommolt, P., & Steger, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074911 · Cited by 37
Locke, M. C., Fox, L. E., Dunlap, B. F., Young, A. R., Monte, K. J., & Lenschow, D. J. (2021) · Journal of Virology · doi:10.1128/jvi.01143-21 · Cited by 32
Kim, M. H., Son, Y., Lee, S. Y., et al. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.10.006 · Cited by 34
Negative Regulation of Interferon-β Gene Expression during Acute and Persistent Virus Infections
Ye, J., & Maniatis, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020681 · Cited by 35
Yuen, C., Chan, C.-P., Fung, S., Wang, P., Wong, W., Tang, H.-M. V., Yuen, K., Chan, C., Jin, D., & Kok, K. (2016) · Journal of Virology · doi:10.1128/jvi.00129-16 · Cited by 38
Wang, S., Sun, X., Yi, C., Zhang, D., Lin, X., Sun, X., Chen, H., & Jin, M. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00195 · Cited by 32
Kim, J., Park, M.-E., Nikapitiya, C., Kim, T., Uddin, M. B., Lee, H., Kim, E., Yeul, J., Jung, J. U., Kim, C., et al. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006398 · Cited by 32
Saikh, K. U., Morazzani, E. M., Piper, A. E., Bakken, R. R., & Glass, P. J. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104854 · Cited by 35
An alternative model for type I interferon induction downstream of human TLR2
Oosenbrug, T., van de Graaff, M. J., Haks, M. C., van Kasteren, S. I., & Ressing, M. E. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.015283 · Cited by 31
Context Is Key: Delineating the Unique Functions of IFNα and IFNβ in Disease
Fox, L. E., Locke, M. C., & Lenschow, D. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.606874 · Cited by 36
Strähle, L., Garcin, D., Mercier, P. L., Schlaak, J., & Kolakofsky, D. (2003) · Journal of Virology · doi:10.1128/jvi.77.14.7903-7913.2003 · Cited by 34
Differential Modification of Interferon Regulatory Factor 3 following Virus Particle Entry
Noyce, R. S., Collins, S. E., & Mossman, K. L. (2009) · Journal of Virology · doi:10.1128/jvi.02069-08 · Cited by 34
c‐MYC Impairs Immunogenicity of Human B Cells
Schlee, M., Schuhmacher, M., Hölzel, M., Laux, G., & Bornkamm, G. W. (2007) · Advances in cancer research · doi:10.1016/s0065-230x(06)97007-9 · Cited by 31
The Short Splice Variant of the γ2 Subunit Acts as an External Modulator of GABA A Receptor Function
Boileau, A. J., Pearce, R. A., & Czajkowski, C. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.5039-09.2010 · Cited by 33
Interleukin-17A Facilitates Chikungunya Virus Infection by Inhibiting IFN-α2 Expression
Neupane, B., Acharya, D., Nazneen, F., Gonzalez-Fernandez, G., Flynt, A. S., & Bai, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.588382 · Cited by 32
The Innate Antiviral Response: New Insights Into A Continuing Story
Paun, A., & Pitha, P. M. (2006) · Advances in virus research · doi:10.1016/s0065-3527(06)69001-5 · Cited by 31
Self-citationSuper-activated interferon-regulatory factors can enhance plasmid immunization
Bramson, J. L., Dayball, K., Hall, J. R., et al. (2003) · Vaccine · doi:10.1016/s0264-410x(02)00694-1 · Cited by 33
Self-citationLuo, H., Zhang, Z., Zheng, Z., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202933 · Cited by 33
Zheng, Z., Yang, J., Jiang, X. J., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701507 · Cited by 33
Pelicano, L., Brumpt, C., Pitha, P. M., & Chelbi‐Alix, M. K. (1999) · Oncogene · doi:10.1038/sj.onc.1202802 · Cited by 32
Self-citationCloning and Functional Analysis of the Human IRF-3 Promoter
Lowther, W. J., Moore, P. A., Carter, K. C., & Pitha, P. M. (1999) · DNA and Cell Biology · doi:10.1089/104454999314962 · Cited by 34
Self-citationKhan, K. A., Dô, F., Marineau, A., Doyon, P., Clément, J.-F., Woodgett, J. R., Doble, B. W., & Servant, M. J. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.00344-15 · Cited by 32
Andrographolide suppresses TRIF-dependent signaling of toll-like receptors by targeting TBK1
Kim, A.-Y., Shim, H., Shin, H., Lee, Y. J., Nam, H., Kim, S. Y., & Youn, H. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.02.019 · Cited by 29
Stavrou, S., Feng, Z., Lemon, S. M., & Roos, R. P. (2010) · Journal of Virology · doi:10.1128/jvi.00603-10 · Cited by 30
Rhesus Cytomegalovirus Particles Prevent Activation of Interferon Regulatory Factor 3
DeFilippis, V. R., & Früh, K. (2005) · Journal of Virology · doi:10.1128/jvi.79.10.6419-6431.2005 · Cited by 32
Li, R. P., Pan, Y., Shi, D., Zhang, Y., & Zhang, J. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.09.001 · Cited by 28
Youn, H., Ahn, S., & Lee, B.-Y. (2008) · International Immunopharmacology · doi:10.1016/j.intimp.2008.10.012 · Cited by 31
Interplay between repressing and activating domains defines the transcriptional activity of IRF-1
Kirchhoff, S., Oumard, A., Nourbakhsh, M., Levi, B.-Z., & Häuser, H. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2000.01750.x · Cited by 31
Hiscott, J., Lacoste, J., & Lin, R. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.06.030 · Cited by 31
Self-citationIκB-Mediated Inhibition of Virus-Induced Beta Interferon Transcription
Algarté-Génin, M., Nguyen, H., Heylbroeck, C., Lin, R., & Hiscott, J. B. (1999) · Journal of Virology · doi:10.1128/jvi.73.4.2694-2702.1999 · Cited by 31
Self-citationYeow, W.-S., Au, W.-C., Lowther, W. J., & Pitha, P. M. (2001) · Journal of Virology · doi:10.1128/jvi.75.6.3021-3027.2001 · Cited by 31
Self-citationFamilial normal tension glaucoma genetics
Fox, A. R., & Fingert, J. H. (2023) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2023.101191 · Cited by 32
Huang, B., Huang, W. S., & Nie, P. (2014) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2014.02.009 · Cited by 30
Wang, Y., Luo, R., Fang, L., et al. (2010) · Molecular Immunology · doi:10.1016/j.molimm.2010.10.022 · Cited by 30
Kennedy, M. A., Hofstadter, W. A., & Cristea, I. M. (2020) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.0c00033 · Cited by 27
Dang, O., Navarro, L., & David, M. (2004) · PubMed · doi:10.1097/01.shk.0000123513.13212.83 · Cited by 30
Bergstrøm, B., Johnsen, I. B., Nguyen, T. T., Hagen, L., Slupphaug, G., Thommesen, L., & Anthonsen, M. W. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.084822 · Cited by 30
Dang, O., Navarro, L., & David, M. (2004) · Shock · doi:10.1097/00024382-200405000-00012 · Cited by 33
IRF3 function and immunological gaps in sepsis
Basak, B., & Akashi‐Takamura, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1336813 · Cited by 30
Huérfano, S., Ryabchenko, B., & Forstová, J. (2013) · DNA and Cell Biology · doi:10.1089/dna.2012.1950 · Cited by 26
A High Resolution Method to Monitor Phosphorylation-dependent Activation of IRF3
Robitaille, A. C., Mariani, M. K., Fortin, A., & Grandvaux, N. (2016) · Journal of Visualized Experiments · doi:10.3791/53723 · Cited by 26
Myeloid neddylation targets IRF7 and promotes host innate immunity against RNA viruses
Zhao, M., Zhang, Y., Yang, X., Jin, J., Shen, Z., Feng, X., Zou, T., Deng, L., Cheng, D., Zhang, X., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009901 · Cited by 28
CD11b agonists offer a novel approach for treating lupus nephritis
Villanueva, V., Li, X., Jiménez, V., Faridi, H. M., & Gupta, V. (2022) · Translational research · doi:10.1016/j.trsl.2022.03.001 · Cited by 29
The IKK Kinases: Operators of Antiviral Signaling
Pham, A. M., & tenOever, B. R. (2010) · Viruses · doi:10.3390/v2010055 · Cited by 27
Johnson, J., Albarani, V., Nguyen, M., Goldman, M., Willems, F., & Aksoy, E. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700421200 · Cited by 29
Bryant-Hudson, K. M., Conrady, C. D., & Carr, D. J. J. (2013) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2013.06.003 · Cited by 28
Yousefi, N., Sotoodehnejadnematalahi, F., Heshmati-Fakhr, N., Sayyah, M., Hoseini, M., Ghassemi, S., Aliakbari, S., & Pourbadie, H. G. (2019) · Journal of Molecular Neuroscience · doi:10.1007/s12031-018-1249-1 · Cited by 28
TANK-binding kinase-1 broadly affects oyster immune response to bacteria and viruses
Tang, X., Huang, B., Zhang, L., et al. (2016) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2016.07.011 · Cited by 28
Duc, G. H. T. (2014) · InTech eBooks · doi:10.5772/57004 · Cited by 28
Assembling the Human IFN-β Enhanceosome in Solution
Dragan, A. I., Carrillo, R., Gerasimova, T. I., et al. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.09.015 · Cited by 28
Role of Hypoxia in the Interferon Response
Arnaiz, E., & Harris, A. L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.821816 · Cited by 28
Zhang, W., Wang, Q., Yang, F., Zhu, Z., Duan, Y., Yang, Y., Cao, W., Zhang, K., Ma, J., Liu, X., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009366 · Cited by 25
Robinson, B. A., Estep, R. D., Messaoudi, I., Rogers, K. S., & Wong, S. W. (2011) · Journal of Virology · doi:10.1128/jvi.05047-11 · Cited by 27
Biological and Clinical Basis for Molecular Studies of Interferons
Pang, K. R., Wu, J. J., Huang, D. B., et al. (2005) · Humana Press eBooks · doi:10.1385/1-59259-939-7:001 · Cited by 27
LYAR Suppresses Beta Interferon Induction by Targeting Phosphorylated Interferon Regulatory Factor 3
Yang, C., Liu, X., Cheng, T., Xiao, R., Gao, Q., Ming, F., Jin, M., Chen, H., & Zhou, H. (2019) · Journal of Virology · doi:10.1128/jvi.00769-19 · Cited by 26
Wressnigg, N., Shurygina, A.-P. S., Wolff, T., Redlberger‐Fritz, M., Popow‐Kraupp, T., Muster, T., Egorov, A., & Kittel, C. (2009) · Journal of General Virology · doi:10.1099/vir.0.006122-0 · Cited by 27
An IRF-3 homolog that is up-regulated by DNA virus and poly I:C in turbot, Scophthalmus maximus
Hu, G., Xia, J., Lou, H., Chen, X., Li, J., & Liu, Q.-M. (2011) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2011.07.011 · Cited by 26
Wuerth, J. D., Habjan, M., Wulle, J., Superti‐Furga, G., Pichlmair, A., & Weber, F. (2018) · Journal of Virology · doi:10.1128/jvi.01202-18 · Cited by 23
The EF-Hand Protein CALML6 Suppresses Antiviral Innate Immunity by Impairing IRF3 Dimerization
Wang, Z., Sheng, C., Yao, C., Chen, H., Wang, D., & Chen, S. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.01.030 · Cited by 26
Munday, D. C., Howell, G. J., Barr, J. N., & Hiscox, J. A. (2014) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12349 · Cited by 25
Identification of novel alternative splicing variants of interferon regulatory factor 3
Li, Y., Hu, X., Song, Y., Lu, Z., Ning, T., Cai, H., & Ke, Y. (2011) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2011.01.006 · Cited by 26
Tsimbalyuk, S., Cross, E. M., Hoad, M., Donnelly, C. M., Roby, J. A., & Forwood, J. K. (2020) · Cells · doi:10.3390/cells9081913 · Cited by 27
Benhelli‐Mokrani, H., Dein, O. S. E., Mansuroglu, Z., & Bonnefoy, E. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00420-06 · Cited by 26
Zolekar, A., Lin, V. J. T., Mishra, N. M., Ho, Y. Y., Hayatshahi, H. S., Parab, A., Sampat, R., Liao, X., Hoffmann, P., Liu, J., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0265-9 · Cited by 24
Functional Characterization of Domains of IPS-1 Using an Inducible Oligomerization System
Takamatsu, S., Onoguchi, K., Onomoto, K., Narita, R., Takahasi, K., Ishidate, F., Fujiwara, T. K., Yoneyama, M., Kato, H., & Fujita, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053578 · Cited by 24
Phosphatases in toll-like receptors signaling: the unfairly-forgotten
Lannoy, V., Côté-Biron, A., Asselin, C., & Rivard, N. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-020-00693-9 · Cited by 27
Yang, N., Luna, J. M., Dai, P., Wang, Y., Rice, C. M., & Deng, L. (2022) · Nature Communications · doi:10.1038/s41467-022-29308-2 · Cited by 25
Bailey, C. M., Margaryan, N. V., Abbott, D. E., et al. (2009) · Development Growth & Differentiation · doi:10.1111/j.1440-169x.2009.01110.x · Cited by 25
HTLV-1 Tax protein recruitment into IKKε and TBK1 kinase complexes enhances IFN-I expression
Diani, E., Avesani, F., Bergamo, E., Cremonese, G., Bertazzoni, U., & Romanelli, M. G. (2014) · Virology · doi:10.1016/j.virol.2014.12.005 · Cited by 29
McGivern, D. R., Villanueva, R. A., Chinnaswamy, S., et al. (2009) · Journal of Virology · doi:10.1128/jvi.00262-09 · Cited by 25
Feng, T., Ta, S., Li, G., Pan, W., Wang, K., & Dai, J. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00356 · Cited by 24
Zhang, W., Li, Z., Jia, P., et al. (2018) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2018.07.014 · Cited by 25
Liu, X., Tang, J., Wang, Z., Zhu, C., Deng, H., Sun, X., Yu, G., Rong, F., Chen, X., Liao, Q., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47814-3 · Cited by 33
Zebrafish Uba1 Degrades IRF3 through K48-Linked Ubiquitination to Inhibit IFN Production
Chen, D., Jiang, J., Lu, L.-F., Zhang, C., Zhou, X.-Y., Li, Z.-C., Zhou, Y., & Li, S. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100125 · Cited by 23
DNA vaccine-mediated innate immune response triggered by PRRs in teleosts
Aoki, T., Takano, T., & Hikima, J.-I. (2015) · Fisheries Science · doi:10.1007/s12562-014-0845-4 · Cited by 24
Marion, J. D., Roberts, C. F., Call, R. J., Forbes, J. L., Nelson, K. T., Bell, J. E., & Bell, J. K. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.440859 · Cited by 24
Innate immune system regulation of nuclear hormone receptors in metabolic diseases
Chow, E. K., Razani, B., & Cheng, G. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.1206741 · Cited by 23
Targeting IRFs by ubiquitination: regulating antiviral responses
Higgs, R., & Jefferies, C. A. (2008) · Biochemical Society Transactions · doi:10.1042/bst0360453 · Cited by 24
Metadata
- Authors
- Lin, R., Heylbroeck, C., Pitha, P. M., & Hiscott, J.
- Affiliations
- Lady Davis Institute for Medical Research (CA)
- Johns Hopkins University (US)
- Corresponding author
- Lin, Rongtuan
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 1998-05-01
- Volume
- 18
- Issue
- 5
- Pages
- 2986-2996
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- PMC
- PMC110678
- OpenAlex
- W2130576390
- Semantic Scholar
- d9395b576923c5fe3c0e57a18df21bd0fd11d519
- Cited by
- 915
- References
- 69
- Citations by year
- 2026: 11 · 2025: 20 · 2024: 24 · 2023: 26 · 2022: 33 · 2021: 24 · 2020: 30 · 2019: 26 · 2018: 27 · 2017: 28 · 2016: 33 · 2015: 26 · 2014: 38 · 2013: 42 · 2012: 30
- FWCI
- 10.65
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Molecular and Cellular Biology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Keywords
- IRF3, interferon regulatory factors, protein phosphorylation, Sendai virus, nuclear translocation, transcriptional activation, interferon-stimulated response element, proteasomal degradation, CREB-binding protein, transcriptional coactivator, post-translational modification, interferon-stimulated genes, phosphomimetic mutations
- MeSH terms
- Amino Acid Sequence, Animals, Biological Transport, Cell Compartmentation, Cell Nucleus, Cysteine Endopeptidases, Cytoplasm, DNA Mutational Analysis, DNA-Binding Proteins, Humans, Molecular Sequence Data, Multienzyme Complexes, Peptide Mapping, Phosphorylation, Protein Binding, Protein Processing, Post-Translational, Transcription Factors, Transcriptional Activation, Trans-Activators, Respirovirus, Proteasome Endopeptidase Complex, Interferon Regulatory Factor-3, Mice, Histone Acetyltransferases, Nuclear Receptor Coactivator 3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review